Short Original

A new SLC12A3 founder mutation (p.Val647Met) in Gitelman’s syndrome patients of Roma ancestry

Helena Gil-Peña\(^a\)*, Eliecer Coto\(^b,f\), Fernando Santos\(^a,f\), Mar Espino\(^c\), Jose M. Ce\(a\) Crespo\(^d\), Giannis Chantzopoulos\(^e\), Filadelfia Komianou\(^e\), Juan Gómez\(^b\), Belén Alonso\(^b\), Sara Iglesias\(^b\), Cyrielle Treard\(^f\), Rosa Vargas-Poussou\(^f\), the Renaltube Group

\(^a\) Dept. Pediatría-RENALTUBE Consortium, Hospital Universitario Central Asturias, Oviedo, Spain
\(^b\) Dept. Genética Molecular-Red de Investigación Renal, Hospital Universitario Central Asturias, Oviedo, Spain
\(^c\) Hospital Doce de Octubre, Madrid, Spain
\(^d\) Hospital Severo Ochoa, Leganés, Spain
\(^e\) Dept. Pediatrics, Aghia Sophia Children's Hospital, Athens, Greece
\(^f\) Hôpital Européen Georges Pompidou, France

**ABSTRACT**

Background: Gitelman’s syndrome (GS) is an autosomal recessive disorder caused by mutations in the SLC12A3 gene. GS is characterized by hypokalaemic metabolic alkalosis, hypomagnesemia and hypocalciuria. Most of the reported patients of Roma ancestry are homozygous for an SLC12A3 intron 9 frameshifting mutation (c.1180+1G>T). Some forms of Bartter’s syndrome result from mutations in the CLNCKB gene and clinically overlap with GS.

Objectives: To characterize a second SLC12A3 mutation in Roma patients negative for the intron 9 variant.

Methods: SLC12A3 and CLNCKB genes were analyzed by next-generation sequencing in two Spanish and Greek gypsy patients who were negative for the intron 9 splicing mutation. Sanger sequencing was performed to confirm the putative mutations in patients and family members.

Results: We identified a missense variant (p.Val647Met, c.1939G>A) in both cases, and both were homozygous for Met. This mutation was also found in three additional patients; two homozygous and one heterozygous compound with the intron 9 splicing mutation. This new SLC12A3 mutation seems to be characteristic of gipsy GS patients and was linked to the same

---

* Corresponding author.
E-mail address: hgilpena@gmail.com (H. Gil-Peña).
http://dx.doi.org/10.1016/j.nefro.2017.01.007
© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Un nuevo modelo de mutación en SLC12A3 (p.Val647Met) en pacientes con síndrome de Gitelman de etnia gitana

Antecedentes: El síndrome de Gitelman (SG) es un trastorno autosómico recesivo causado por las mutaciones en el gen SLC12A3. El SG se caracteriza por una alcalosis metabólica hipokalémica, hipomagnesemia e hipocalcúria. La mayoría de los pacientes de etnia gitana presentan mutaciones homocigotas para la mutación con desplazamiento del marco de lectura del intrón 9 de SLC12A3 (c.1180+1G>T). Algunas formas del síndrome de Bartter proceden de las mutaciones del gen CLNKB y se solapan clínicamente con el SG.

Objetivos: Determinar las características de una segunda mutación en SLC12A3 en pacientes de etnia gitana con resultados negativos en la variante intrón 9.

Métodos: Se analizaron los genes SLC12A3 y CLNKB mediante secuenciación de nueva generación en 2 pacientes –uno español y otro griego– de etnia gitana con resultados negativos en la mutación de empalme del intrón 9. Se llevó a cabo una secuenciación de Sanger para confirmar las supuestas mutaciones en los pacientes y sus familiares.

Resultados: Se identificó una variante con cambio de sentido (p.Val647Met, c.1939G>T) en ambos casos, y ambos eran homocigotos con respecto a Met. También se observó esta mutación en 3 pacientes adicionales, 2 homocigotos y uno heterocigoto compuesto con la mutación del intrón 9. Esta nueva mutación del SLC12A3 parece ser característica de los pacientes con SG de etnia gitana y se relacionó con el mismo haplótipo en todos los casos, lo que indica un origen fundador. Todos los pacientes presentaron rasgos bioquímicos propios del SG.

Conclusión: Informamos de una segunda mutación fundadora en los pacientes con SG de etnia gitana. El cribado genético directo de esta mutación facilitará la determinación de las características de los pacientes con resultados negativos en la mutación del intrón 9 +1G>T, que es más frecuente.

© 2017 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 – Serum biochemistry and genetic data of the affected members in the five families.

<table>
<thead>
<tr>
<th>Kindred</th>
<th>Sex</th>
<th>Age at diagnosis</th>
<th>pH</th>
<th>HCO₃⁻ (mEq/L)</th>
<th>K⁺ (mEq/L)</th>
<th>Mg²⁺ (mg/dL)</th>
<th>Mutations in SLC12A3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family I</td>
<td>PI.1</td>
<td>Male</td>
<td>14 years</td>
<td>7.61</td>
<td>30</td>
<td>2.1</td>
<td>1.40</td>
</tr>
<tr>
<td></td>
<td>PI.1.1</td>
<td>Female</td>
<td>11 months</td>
<td>7.50</td>
<td>28</td>
<td>3.9</td>
<td>1.50</td>
</tr>
<tr>
<td></td>
<td>PI.1.2</td>
<td>Female</td>
<td>7 months</td>
<td>7.50</td>
<td>NA</td>
<td>NA</td>
<td>1.83</td>
</tr>
<tr>
<td></td>
<td>PI.1.3</td>
<td>Male</td>
<td>11 months</td>
<td>7.44</td>
<td>24.5</td>
<td>3.72</td>
<td>2.10</td>
</tr>
<tr>
<td>Family II</td>
<td>PI.I</td>
<td>Female</td>
<td>11 months</td>
<td>7.44</td>
<td>24.5</td>
<td>3.72</td>
<td>2.10</td>
</tr>
<tr>
<td></td>
<td>PI.I.1</td>
<td>Female</td>
<td>29 months</td>
<td>7.48</td>
<td>28</td>
<td>2.5</td>
<td>1.80</td>
</tr>
<tr>
<td>Family III</td>
<td>PI.I.2</td>
<td>Male</td>
<td>7 months</td>
<td>7.51</td>
<td>NA</td>
<td>1.8</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>PI.I.3</td>
<td>Male</td>
<td>11 months</td>
<td>7.44</td>
<td>24.5</td>
<td>3.72</td>
<td>2.10</td>
</tr>
<tr>
<td>Family IV</td>
<td>PI.IV.1</td>
<td>Male</td>
<td>49 years</td>
<td>NA</td>
<td>30.6</td>
<td>2.4</td>
<td>1.58</td>
</tr>
<tr>
<td>Family V</td>
<td>PV.I</td>
<td>Male</td>
<td>33 years</td>
<td>NA</td>
<td>34</td>
<td>2.6</td>
<td>0.96</td>
</tr>
</tbody>
</table>

K⁺: potassium; Mg²⁺: magnesium; HCO₃⁻: bicarbonate; Val: valine; Met: methionine. NA: data not available.

Fig. 1 – Pedigrees of the five families. A and B represents the haplotypes containing the p.647 Met. *Intron 9 GAT-repeats not available.
in the presence of founder-mutations for several inherited disorders. To date, most of the reported Gypsy patients having GS are homozygous for the intron 9 +1G>T mutation (c.1180+1G>T). Here, we describe a new SLC12A3 mutation characteristic of Roma SG patients.

Methods

Patients

We studied eight patients from five families diagnosed of GS (Table 1). The five families had a Roma ethnic background and traced their ancestry to the South-East European region, including the Spanish family whose ancestors emigrated from Romania two generations ago. The Spanish and Greek families were recruited through the Renaltube Consortium (www.renaltube.com).

Genetic study

The search for SLC12A3 and CLCNKB mutations was first performed in the index cases from families I and II. The two were negative for the intron 9 splicing mutation. The whole coding plus at least 5 intronic flanking nucleotides were sequenced through semiconductor Next Generation Sequencing (NGS) with the Ion Torrent Personal Genome Machine (PGM, Life Technologies), following a previously reported procedure.

To confirm the putative mutations identified by NGS, the corresponding exons were amplified and sequenced by the Sanger method. This procedure was also used to determine the presence of the mutation in all the family members.

To characterize the haplotypes linked to the SLC12A3 mutation, five common single nucleotide polymorphisms were determined by Sanger sequencing of PCR fragments: rs5801 (c.1395C>T), rs2304483 (c.1670−8T>C), rs13306676 (c.2179−8C>T), rs34772420 (c.2748−13T>C), and rs2289115 (c.2951+13C>T). In families I and II we also genotyped an intron 9 repeat polymorphism.

Results

Clinical data

Family I had several GS patients in two generations. The index case (PI.1) was the father of three children with mild clinical features of GS. The father was diagnosed in the adolescence whereas the three siblings were diagnosed before the age of two years. Three brothers and one sister of the index case presented also GS findings such as hypokalemia, hypomagnesaemia and elevated bicarbonate serum values with a blood pH > 7.35 (data not showed).

Genotype

The NGS of SLC12A3 and CLCNKB in the index cases from families I and II revealed the presence of a nucleotide variant in exon 16 of SLC12A3 (c.1939G>A) that would result in a missense amino acid change (p.Val647Met). This variant is predicted to be pathogenic/deleterious by the bioinformatic programs SIFT (http://sift.jcvi.org) and Polyphen (http://genetics.bwh.harvard.edu/pph2). The Sanger sequencing of exon 16 fragments showed that these patients were...
homoygous for the mutation, and we also determined the mutation genotype in all the family members (Fig. 1).

The analysis of the five SLC12A3 SNPs showed that the p.647 Val mutation was in the same haplotype in the five families (Fig. 1).

Discussion

More than 180 mutations in SLC12A3 gene have been reported in GS patients.1 There is not a prevalent mutation, and this means that the sequencing of the 26 SLC12A3 exons is required to search for mutations in most of the GS patients.15,16 Moreover, CLCNKB mutations may be found in some cases with clinical manifestations of GS, a fact that increases the complexity of the genetic study of GS. Thus, the discovery of mutations common in an ethnic group will facilitate the genetic analysis by limiting the sequencing to one or few exons.10

In this article we present Gypsy cases from Spain and Greece with the same mutation in the SLC12A3 gene. Patients were recruited through the Renaltube Consortium13 which collects data from patients worldwide in an attempt to better define the clinical profile and the genetic background of renal tubulopathies. To date, >50 Gypsy GS patients are included in the Renaltube database and most of these patients are homozygous for the intron 9 splicing mutation. The index cases of Families I and II, were subjected to NGS to search for new SLC12A3 mutations, resulting in the identification of p.Val647Met. The p.Val647Met variant was predicted to be pathogenic with at least two bioinformatic programs (SIFT and PolyPhen). This missense change locates at the intracellular carboxy-end of the protein (Fig. 2), where other GS mutations have been found and aminoacids at this region are conserved not only among species but also in other human channels such as bumetanide-sensitive cotransporter (SLC12A2 gene).17

The p.Val647Met mutation had been previously reported by Vargas-Poussou et al. in one GS patient (PV.1) compound heterozygous for this variant and the intron 9 mutation.7 Thus, the two families we studied and the three previously reported by Vargas et al.7 had a common Gypsy genetic background and traced their ancestry to South-Eastern Europe. The p.Val647Met was linked to the same SLC12A3 polymorphisms in the 5 families, a fact that strongly supports a common origin for this new Gypsy GS

In conclusion, we report a new SLC12A3 founder mutation among GS patients of Gypsy background, p.Val647Met. This mutation was associated with typical clinical features of GS, either in homozygosity or in combination with the intron 9+1G>A mutation. Our finding facilitates the diagnosis of GS in Gypsy patients.

Compliance with ethical standards

All the patients/participants in the study gave their informed consent, approved by the Ethical Committee of Hospital Universitario Central Asturias.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

This work has been supported by grant PI14/00702, Plan Nacional de I+D+i 2013–2016 and funded by ISCIII, Fondo Europeo de Desarrollo Regional (FEDER).

References

14. Tavira B, Gómez J, Santos F, Gil H, Alvarez V, Coto E. A labor-
and cost effective non-optical semiconductor (Ion Torrent)
next-generation sequencing of theSLC12A3 and CLCNKA/B

15. Wang F, Shi C, Cui Y, Li C, Tong A. Mutation profile and 
Exp Nephrol. 2016, 
Exp Nephrol. 2017; doi:10.1007/s10157-017-1389-6

16. Wolyniec W, Jakubowska SK, Nagel M, Wolyniec Z, 
of Gitelman syndrome resulting from two novel mutations in 

17. Lemmink HH, Knoers NV, Károlyi L, van Dijk H, Niaudet P, 
Antignac C, et al. Novel mutations in the thiazide-sensitive 
NaCl cotransporter gene in patients with Gitelman syndrome 
with predominant localization to the C-terminal domain. 